Acquired Hemophilia A Revealing Occult Splenic Marginal Zone Lymphoma

17 July 2026 : Case report USA

Challenging differential diagnosis, Rare disease

Haripriya Susmitha Brahmanapalle^{ABDEF 1*}, Alka Arora^{DF 2}

DOI: 10.12659/AJCR.953683

Am J Case Rep 2026; 27:e953683

Authors information Article notes Copyright and License information

Introduction Case Report Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 1 Patient’s clinical course, treatment timeline, and laboratory response.

Parameter	Admission*	Discharge**	First follow-up***	Sep 25	Oct 25	Nov 2025 admission	Dec 25	Feb 26
	11.5 (nadir 8.1)	10	11.6	13.2	14.4	11–12	13.7	14.8
	83 (nadir 52)	~ 50–70	71	~ 70	~ 99	~ 100	131	98
	72–98 (peak > 90)	57	Improved	31	Normal	Normal	Normal	~ 35
	2	2	5	53	118	Normal	215	59
	7.1	7.1	—	0.8	—	—	—	—
	317	—	314	246	223	—	170	225
	FEIBA + steroids	Prednisone	Prednisone continued, rituximab initiated	Steroid taper	Rituximab completed, steroid taper	Hospitalization for neutropenic diverticulitis, steroid taper	Off steroids	Surveillance
Footnotes: ^* 8/14/2025; ^ 8/21/2025; ^* 8/27/2025. Reference ranges: Hemoglobin 13.5–17.5 g/dL; platelets 150–450 × 10/L; aPTT 25–35 seconds; factor VIII activity 50–150%; factor VIII inhibitor < 0.6 BU. aPTT, activated partial thromboplastin time; FVIII, factor VIII; BU, Bethesda Units; FEIBA, factor VIII inhibitor bypassing activity.

Back to the Article